APP下载

静脉给予两次低剂量重组人脑利钠肽治疗顽固性心衰的疗效及安全性

2016-01-11杜贺,唐念中,陈少萍

药学服务与研究 2015年2期
关键词:心力衰竭安全性

·论著·

静脉给予两次低剂量重组人脑利钠肽治疗顽固性心衰的疗效及安全性

杜贺,唐念中,陈少萍*(第二军医大学长海医院心血管内科,上海 200433)

[摘要]目的:观察冻干重组人脑利钠肽(新活素,recombinant human brain natriuretic peptide,rhBNP)治疗顽固性心衰(refractory heart failure,RHF) 的疗效与安全性。方法: 2013年2月至2014年5月第二军医大学长海医院心血管内科收治的RHF病人78例,随机分为对照组和rhBNP组,每组39例。在常规抗心衰治疗的基础上,rhBNP组给予rhBNP治疗,先在10 min内匀速静脉注射负荷剂量1.5 μg/kg,随后以0.01 μg·kg-1·min-1维持静脉泵入(至少10 h泵入),每次总量0.5 mg,隔3 d再重复给药1次。第2次用药后7 d,比较两组病人的心功能分级、脑利钠肽(BNP)和肌酐水平、左室射血分数(LVEF)、左室舒张末内径(LVEDD),并记录不良反应。结果: rhBNP 组心功能改善36例,总有效率为92.31%,显著高于对照组的28例(71.79%,P<0.05)。两组病人用药后心率减慢,舒张压、肌酐和BNP降低,LVEF提高,LVEDD减小,与用药前比较差异有极显著意义(P<0.001),且rhBNP组心率、舒张压、LVEDD、血肌酐和BNP水平的降低,和LVEF的提高比对照组更明显(P<0.001)。rhBNP组发生1例低血压和1例低血钾,对照组发生2例低血压和1例室性心律失常,两者不良事件无显著差异(P>0.05)。结论: 在常规抗心衰治疗基础上再静脉给予两次rhBNP(间隔3 d),可以进一步改善RHF病人的心功能和血流动力学,降低血浆BNP和血清肌酐水平,使疗效提高,但并不增加不良反应。

[关键词]心力衰竭;重组人脑利钠肽;药物疗法;安全性

[中图分类号]R541.61[文献标志码]A

DOI:10.5428/pcar20150209

作者简介杜贺(女),硕士生.E-mail:916276740@qq.com

[收稿日期]2015-01-04

*通信作者(Corresponding author):陈少萍,E-mail:cspcsp67@sina.com

Efficacy and safety of two intravenous medications of low-dose recombinant human brain natriuretic peptide in patients with refractory heart failure

DU He,TANG NianZhong,CHEN ShaoPing*(Department of Cardiovasology,Changhai Hospital,Second Military Medical University,Shanghai 200433,China)

ABSTRACT[]Objective:To observe the efficacy and safety of two intravenous medications of low-dose recombinant human brain natriuretic peptide (rhBNP) in patients with refractory heart failure (RHF). Methods:Seventy-eight patients with RHF admitted into the Department of Cardiovasology of Changhai Hospital, Second Military Medical University from February,2013 to May,2014 were randomly divided into the control and the rhBNP groups,each consisting of 39 patients. On the basis of routine drug treatment of heart failure,rhBNP was given to the patients in the rhBNP group. Intravenous rhBNP at a loading dose of 1.5 μg/kg was given uniformly within 10 min,then,continuous infusion of rhBNP at a rate of 0.01 μg·kg-1·min-1 was pumped in over 10 hours,with a total amount of 0.5 mg. On day 4,another dose of 0.5 mg rhBNP was given in the same way. After 7 days of the second medication,the cardiac function,levels of plasma brain natriuretic peptide (BNP) and serum creatinine,left ventricular ejection fraction (LVEF),left ventricular end-diastolic diameter (LVEDD) and the adverse reactions were compared between the 2 groups. Results:For the rhBNP group,cardiac function of the 36 patients was improved,with a total effective rate of 92.31%,which was significantly higher,as compared with 71.79% of the control group (28 patients) (P<0.05). Heart rate (HR),diastolic blood pressure (DBP),levels of plasma BNP and serum creatinine,and LVEDD were all significantly decreased,and the level of LVEF was increased for the patients of both groups,following medication. Significant differences could be noted,as compared with the data before medication (P<0.001). HR,DBP,levels of LVEDD,serum creatinine and plasma BNP were all decreased,while the level of LVEF was increased for the patients of the rhBNP group,which were significantly higher than those of the control group (P<0.001). One case of hypotension and one case of hypopotassemia were observed in the rhBNP group,and 2 cases of hypotension and one case of ventricular arrhythmia occurred in the control group. No significant differences could be noticed in adverse events,when comparisons were made between the 2 groups (P>0.05).Conclusion: On the basis of traditional drug treatment,2 intravenous medications of low-dose rhBNP (with an interval of 3 days between medications) could further improve cardiac function and hemodynamics,and decrease BNP and creatinine levels of the patients with RHF,thus improving the efficacy without obvious adverse reactions.

[KEY WORDS]heart failure;recombinant human brain natriuretic peptide;drug therapy;safety

[Pharm Care Res,2015,15(2):115-118]

慢性心衰病人经过优化的内科治疗,消除并发症和诱因后,心衰症状和临床状态未能得到改善甚至有恶化倾向者,称为顽固性心衰(refractory heart failure,RHF)。RHF属于ACCF/AHA心力衰竭分期D期,主要见于已进入末期的严重器质性心脏病病人,常常需要静脉持续给予强心剂和利尿剂纠正心衰,或采用非药物的器械治疗以改善症状[1]。对RHF治疗目的是迅速改善症状、延缓病程进展和降低病死率。……

登录APP查看全文

猜你喜欢

心力衰竭安全性
两款输液泵的输血安全性评估
既有建筑工程质量安全性的思考
某既有隔震建筑检测与安全性鉴定
米氮平治疗老年失眠伴抑郁症的疗效及安全性
BNP、甲状腺激素水平在老年心衰患者病情及预后判断中的价值
婴儿肺炎合并心力衰竭的临床护理分析
中药汤剂联合中药足浴及耳穴压豆治疗慢性心力衰竭的临床观察
冠心病心力衰竭应用美托洛尔联合曲美他嗪治疗的疗效分析
心力衰竭合并室性心律失常的诊断和治疗进展
ApplePay横空出世 安全性遭受质疑 拿什么保护你,我的苹果支付?